Alvotech and Teva have received permission from the Food and Drug Administration for Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult ...

Teva Pharmaceuticals and Alvotech are introducing Simlandi (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to AbbVie’s Humira for the treatment of adult rheumatoid arthritis, ...

Jan 3 (Reuters) - CVS Health CVS.N said on Wednesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CVS will remove Abbvie's Humira ...

A year ago, Blue Shield of California announced that it would move on from a traditional pharmacy benefit management relationship with CVS' Caremark and instead adopt a new model that leans on ...

AbbVie’s Humira sales slipped last year as the Big Pharma dealt with the first real generic erosion of its immunology megablockbuster, but its backup meds will be more than enough to not just shore up ...

The Food and Drug Administration has accepted for review an application from Amgen for a biosimilar drug to compete with AbbieVie Inc.’s Humira. Amgen in Thousand Oaks calls its drug ABP 501. Humira ...

AbbVie posted first-quarter results largely as projected, and we don’t expect any major changes to our fair value estimate. With the arrival of the first U.S. biosimilar to Humira, AbbVie’s results ...

CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter of ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...